Advanced molecular pathology for rare tumours : A national feasibility study and model for centralised medulloblastoma diagnostics
© 2021 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society..
AIMS: Application of advanced molecular pathology in rare tumours is hindered by low sample numbers, access to specialised expertise/technologies and tissue/assay QC and rapid reporting requirements. We assessed the feasibility of co-ordinated real-time centralised pathology review (CPR), encompassing molecular diagnostics and contemporary genomics (RNA-seq/DNA methylation-array).
METHODS: This nationwide trial in medulloblastoma (<80 UK diagnoses/year) introduced a national reference centre (NRC) and assessed its performance and reporting to World Health Organisation standards. Paired frozen/formalin-fixed, paraffin-embedded tumour material were co-submitted from 135 patients (16 referral centres).
RESULTS: Complete CPR diagnostics were successful for 88% (120/135). Inadequate sampling was the most common cause of failure; biomaterials were typically suitable for methylation-array (129/135, 94%), but frozen tissues commonly fell below RNA-seq QC requirements (53/135, 39%). Late reporting was most often due to delayed submission. CPR assigned or altered histological variant (vs local diagnosis) for 40/135 tumours (30%). Benchmarking/QC of specific biomarker assays impacted test results; fluorescent in-situ hybridisation most accurately identified high-risk MYC/MYCN amplification (20/135, 15%), while combined methods (CTNNB1/chr6 status, methylation-array subgrouping) best defined favourable-risk WNT tumours (14/135; 10%). Engagement of a specialist pathologist panel was essential for consensus assessment of histological variants and immunohistochemistry. Overall, CPR altered clinical risk-status for 29% of patients.
CONCLUSION: National real-time CPR is feasible, delivering robust diagnostics to WHO criteria and assignment of clinical risk-status, significantly altering clinical management. Recommendations and experience from our study are applicable to advanced molecular diagnostics systems, both local and centralised, across rare tumour types, enabling their application in biomarker-driven routine diagnostics and clinical/research studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Neuropathology and applied neurobiology - 47(2021), 6 vom: 15. Okt., Seite 736-747 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Crosier, Stephen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 28.01.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/nan.12716 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323820425 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323820425 | ||
| 003 | DE-627 | ||
| 005 | 20231225185011.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/nan.12716 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1079.xml |
| 035 | |a (DE-627)NLM323820425 | ||
| 035 | |a (NLM)33826763 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Crosier, Stephen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Advanced molecular pathology for rare tumours |b A national feasibility study and model for centralised medulloblastoma diagnostics |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.01.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society. | ||
| 520 | |a AIMS: Application of advanced molecular pathology in rare tumours is hindered by low sample numbers, access to specialised expertise/technologies and tissue/assay QC and rapid reporting requirements. We assessed the feasibility of co-ordinated real-time centralised pathology review (CPR), encompassing molecular diagnostics and contemporary genomics (RNA-seq/DNA methylation-array) | ||
| 520 | |a METHODS: This nationwide trial in medulloblastoma (<80 UK diagnoses/year) introduced a national reference centre (NRC) and assessed its performance and reporting to World Health Organisation standards. Paired frozen/formalin-fixed, paraffin-embedded tumour material were co-submitted from 135 patients (16 referral centres) | ||
| 520 | |a RESULTS: Complete CPR diagnostics were successful for 88% (120/135). Inadequate sampling was the most common cause of failure; biomaterials were typically suitable for methylation-array (129/135, 94%), but frozen tissues commonly fell below RNA-seq QC requirements (53/135, 39%). Late reporting was most often due to delayed submission. CPR assigned or altered histological variant (vs local diagnosis) for 40/135 tumours (30%). Benchmarking/QC of specific biomarker assays impacted test results; fluorescent in-situ hybridisation most accurately identified high-risk MYC/MYCN amplification (20/135, 15%), while combined methods (CTNNB1/chr6 status, methylation-array subgrouping) best defined favourable-risk WNT tumours (14/135; 10%). Engagement of a specialist pathologist panel was essential for consensus assessment of histological variants and immunohistochemistry. Overall, CPR altered clinical risk-status for 29% of patients | ||
| 520 | |a CONCLUSION: National real-time CPR is feasible, delivering robust diagnostics to WHO criteria and assignment of clinical risk-status, significantly altering clinical management. Recommendations and experience from our study are applicable to advanced molecular diagnostics systems, both local and centralised, across rare tumour types, enabling their application in biomarker-driven routine diagnostics and clinical/research studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a biomaterial | |
| 650 | 4 | |a diagnostics | |
| 650 | 4 | |a molecular pathology | |
| 650 | 4 | |a pathology review | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 700 | 1 | |a Hicks, Debbie |e verfasserin |4 aut | |
| 700 | 1 | |a Schwalbe, Edward C |e verfasserin |4 aut | |
| 700 | 1 | |a Williamson, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Leigh Nicholson, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Lindsey, Janet C |e verfasserin |4 aut | |
| 700 | 1 | |a Michalski, Antony |e verfasserin |4 aut | |
| 700 | 1 | |a Pizer, Barry |e verfasserin |4 aut | |
| 700 | 1 | |a Bailey, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Bown, Nick |e verfasserin |4 aut | |
| 700 | 1 | |a Cuthbert, Gavin |e verfasserin |4 aut | |
| 700 | 1 | |a Wharton, Stephen B |e verfasserin |4 aut | |
| 700 | 1 | |a Jacques, Thomas S |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Abhijit |e verfasserin |4 aut | |
| 700 | 1 | |a Clifford, Steven C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuropathology and applied neurobiology |d 1993 |g 47(2021), 6 vom: 15. Okt., Seite 736-747 |w (DE-627)NLM000359491 |x 1365-2990 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2021 |g number:6 |g day:15 |g month:10 |g pages:736-747 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/nan.12716 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2021 |e 6 |b 15 |c 10 |h 736-747 | ||